1-5 of 5
Pierre Squifflet
Close
Sort by
Journal Articles

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Alison J. Forgie, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MDPhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-135941
Published: 2020
Journal Articles

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MD PhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1953.
https://doi.org/10.1182/blood-2019-123219
Published: 2019
Journal Articles

Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib

Pierre Squifflet, Master of Science in Statistics, Stefan Michiels, David S. Siegel, MD, PhD, Ravi Vij, MD, Sunhee Ro, Ph.D., Marc E Buyse, ScD
Journal: Blood
Blood (2011) 118 (21): 1877.
https://doi.org/10.1182/blood.V118.21.1877.1877
Published: 2011
Journal Articles

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

Clinical Trials & Observations
Marc Buyse, Pierre Squifflet, Beverly J. Lange, Todd A. Alonzo, Richard A. Larson, Jonathan E. Kolitz, Stephen L. George, Clara D. Bloomfield, Sylvie Castaigne, Sylvie Chevret, Didier Blaise, Dominique Maraninchi, Kathryn J. Lucchesi, Tomasz Burzykowski
Journal: Blood
Blood (2011) 117 (26): 7007–7013.
https://doi.org/10.1182/blood-2011-02-337725
Published: 2011
Includes: Supplemental data
Journal Articles

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Assessment of Consistency and Robustness of Treatment Benefit for Patients in First Complete Remission.

Marc E Buyse, ScD, Pierre Squifflet, MSc, Jacob M Rowe, MD, John K Whisnant, MD, Dileep Bhagwat, PhD, MBA, Stephane E Allard, MD, Kristoffer Hellstrand, MD, PhD, Mats L Brune, MD
Journal: Blood
Blood (2008) 112 (11): 1948.
https://doi.org/10.1182/blood.V112.11.1948.1948
Published: 2008